Amino focuses on targeted nutrition using amino acids to improve human health, emphasizing the untapped potential beyond sports and bodybuilding. Currently offering pre- and intra-workout amino acid drinks, the company aims to expand its product line to cater to a broader consumer base, believing the market lacks variety in ready-to-mix powdered blends. Backed by scientific research and a commitment to taste and accessibility, Amino aspires to emerge as the leading global brand in amino acid products.
read more
read less
Log in to view amount pledged
Log in to view target
£2,782,057
pre-money valuation
5.76%
equity available
129
investors
£1,495
pledge per investor
11121729
company number
Active
company status
Officers
Simon CARTY
Appointed: 21-12-2017
Valuations in Health and Fitness
| Clinical Net | £7.5M |
| Carocell Bio Limited | £6.1M |
| Swing | £5.9M |
| PulmoBioMed | £4.0M |
| Optimise BP | £10.0 |
More from Health and Fitness
Swing has pioneered an IoT-connected micro-gym, the Swing Box, equipped with integrated free weights suitable for outdoor use. This innovative gym solution includes adjustable backrests and various dumbbells and kettlebells, catering to users of all fitness levels. Users can conveniently locate, reserve, and unlock the Swing Box using any smartphone, aiming to combat physical inactivity, which contributes to a significant number of deaths and costs the UK £7.4 billion annually. Swing's solution addresses the barriers of affordability, accessibility, and time in exercise by providing on-demand, free-access outdoor micro-gyms in communal parks and green spaces. With over 90% of UK residents within a 10-minute walk of public parks and only 32% meeting NHS guidelines for muscle-strength activity, Swing aims to lease these boxes to grant public access with leaseholders paying an annual fee of £2500 per box, covering maintenance and operations.
days to go:
9
investment:
£245,544
Clinical Net is a health-tech firm focused on revolutionizing access to innovative clinical trials. Their AI platform swiftly connects patients with suitable trials, addressing the challenge of low participation rates and delays that hinder pharmaceutical research. With over 69,000 trials globally, their solution aims to streamline the cumbersome and time-consuming process of trial matching, making it more efficient and accessible within 5 minutes. This innovative approach targets the $3.73 billion patient recruitment market while ensuring individuals have easier access to groundbreaking treatments.
days to go:
2
investment:
£130,059
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
6
investment:
Withheld
